Publications by authors named "ShuangYi Lei"
Background: Primary Pulmonary Lymphoepithelioma-like Carcinoma (PPLELC) is a rare form of cancer for which no standard treatment has been established to date. Patients with advanced-stage PPLELC generally have a poor prognosis with overall survival of 22.7 months.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluates the effectiveness and safety of combining fruquintinib with sintilimab (FS) versus trifluridine and tipiracil (TAS-102 or FT) in patients with metastatic colorectal cancer (mCRC) who have exhausted second-line treatments.
- - Results showed that the FS group had a higher disease control rate (80.9% vs. 55.6%) and better median progression-free survival (6.0 months vs. 3.5 months), indicating FS is more effective than FT for these patients.
- - Most side effects reported were mild (grade 1-2), suggesting that the FS treatment is better tolerated, potentially positioning the combination of fruqu
For patients with advanced gastric cancer after chemotherapy, the optimal mode of maintenance therapy is not yet clear. This research aimed to compare the efficacy and adverse effects of S-1 maintenance therapy and follow-up observation in patients with advanced gastric cancer without disease progression after first-line combined chemotherapy. This study retrospectively analyzed 106 patients from January 2018 to December 2021.
View Article and Find Full Text PDFObjective: To explore HIF1α and HIF2α regulate the dedifferentiation of lung cancer cells under hypoxic conditions through Sox2 and Oct4.
Materials And Methods: HIF1α, HIF2α, Sox2 and Oct4 expression was analysed in lung cancer tissues. We analysed sphere formation by single-cell of differentiated lung cancer under hypoxia, and detected the expression of CD133, CD44, Sox2, Oct4, HIF1α and HIF2α.
Background: Keeping on original epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment is the standard treatment for gradual progression EGFR-positive metastatic non-small cell lung cancer (NSCLC). Angiogenic pathway can lead to EGFR-TKI resistance, but the effectiveness of combination strategies in this group is still controversial. This study aimed to assess the efficacy and safety of the original EGFR-TKI combined with bevacizumab in advanced and metastatic lung adenocarcinoma patients harboring EGFR-mutation who experience gradual progression in a real-world setting.
View Article and Find Full Text PDFIntroduction: Circular RNAs (circRNAs) are deregulated in many types of human cancers, including non-small cell lung cancer (NSCLC). In this study, we aimed to explore the functional role of circMYLK in NSCLC.
Materials And Methods: The expression levels of circMYLK and miR-195-5p in NSCLC tissues and cell lines were detected by RT-qPCR analysis.